Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)
NCT ID: NCT03211702
Last Updated: 2023-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2017-08-25
2020-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma
NCT02555267
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
NCT01829958
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT04113226
A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT01676558
Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma
NCT03513601
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elderly DLBCL patients
Elderly DLBCL patients (age\>=65 years) treated with R-CHOP chemotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 65 years old or over
* Scheduled to receive R-CHOP chemotherapy
* Informed consent
Exclusion Criteria
* Primary central nervous system DLBCL
* Patients with a diagnosis of cancer (other than basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, well differentiated thyroid cancer \[papillary or follicular thyroid cancer\]) within 3 years before the study entry or with any treatment for cancer within 3 years before entry
* Consent withdrawal
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Catholic University of Korea
OTHER
Kyungpook National University Hospital
OTHER
Keimyung University Dongsan Medical Center
OTHER
Korea University Anam Hospital
OTHER
Korea University Guro Hospital
OTHER
Kosin University Gospel Hospital
OTHER
Pusan National University Hospital
OTHER
Soonchunhyang University Hospital
OTHER
Ajou University School of Medicine
OTHER
Chonnam National University Hospital
OTHER
Chungnam National University Hospital
OTHER
Yeungnam University Hospital
OTHER
Chonbuk National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ho-Young Yhim
Assistant professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chonnam National University Hwasun Hospital
Hwasun, , South Korea
Chonbuk National University Hospital
Jeonju, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GERIAD2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.